191 related articles for article (PubMed ID: 11082323)
1. Germline incorporation of a replication-defective adenoviral vector in mice does not alter immune responses to adenoviral vectors.
Camargo FD; Huey-Louie DA; Finn AV; Sassani AB; Cozen AE; Moriwaki H; Schneider DB; Agah R; Dichek DA
Mol Ther; 2000 Nov; 2(5):496-504. PubMed ID: 11082323
[TBL] [Abstract][Full Text] [Related]
2. 'Autoreplication' of the vector genome in recombinant adenoviral vectors with different E1 region deletions and transgenes.
Marienfeld U; Haack A; Thalheimer P; Schneider-Rasp S; Brackmann HH; Poller W
Gene Ther; 1999 Jun; 6(6):1101-13. PubMed ID: 10455413
[TBL] [Abstract][Full Text] [Related]
3. Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministered antigen: the role of nitric oxide.
Lasarte JJ; Corrales FJ; Casares N; López-Díaz de Cerio A; Qian C; Xie X; Borrás-Cuesta F; Prieto J
J Immunol; 1999 May; 162(9):5270-7. PubMed ID: 10228002
[TBL] [Abstract][Full Text] [Related]
4. Improved vascular gene transfer with a helper-dependent adenoviral vector.
Wen S; Graf S; Massey PG; Dichek DA
Circulation; 2004 Sep; 110(11):1484-91. PubMed ID: 15326058
[TBL] [Abstract][Full Text] [Related]
5. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice.
Fields PA; Armstrong E; Hagstrom JN; Arruda VR; Murphy ML; Farrell JP; High KA; Herzog RW
Gene Ther; 2001 Mar; 8(5):354-61. PubMed ID: 11313811
[TBL] [Abstract][Full Text] [Related]
6. Neonatal cotton rats do not exhibit destructive immune responses to adenoviral vectors.
Zepeda M; Wilson JM
Gene Ther; 1996 Nov; 3(11):973-9. PubMed ID: 8940637
[TBL] [Abstract][Full Text] [Related]
7. Intranasal vaccination with a helper-dependent adenoviral vector enhances transgene-specific immune responses in BALB/c mice.
Fu YH; He JS; Zheng XX; Wang XB; Xie C; Shi CX; Zhang M; Tang Q; Wei W; Qu JG; Hong T
Biochem Biophys Res Commun; 2010 Jan; 391(1):857-61. PubMed ID: 19945423
[TBL] [Abstract][Full Text] [Related]
8. An immunomodulatory procedure that stabilizes transgene expression and permits readministration of E1-deleted adenovirus vectors.
Kuzmin AI; Galenko O; Eisensmith RC
Mol Ther; 2001 Mar; 3(3):293-301. PubMed ID: 11273770
[TBL] [Abstract][Full Text] [Related]
9. Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector.
Van Linthout S; Lusky M; Collen D; De Geest B
Gene Ther; 2002 Nov; 9(22):1520-8. PubMed ID: 12407424
[TBL] [Abstract][Full Text] [Related]
10. Repeated administration of adenoviral vectors in lungs of human CD4 transgenic mice treated with a nondepleting CD4 antibody.
Chirmule N; Truneh A; Haecker SE; Tazelaar J; Gao Gp; Raper SE; Hughes JV; Wilson JM
J Immunol; 1999 Jul; 163(1):448-55. PubMed ID: 10384148
[TBL] [Abstract][Full Text] [Related]
11. Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo.
Muruve DA; Cotter MJ; Zaiss AK; White LR; Liu Q; Chan T; Clark SA; Ross PJ; Meulenbroek RA; Maelandsmo GM; Parks RJ
J Virol; 2004 Jun; 78(11):5966-72. PubMed ID: 15140994
[TBL] [Abstract][Full Text] [Related]
12. Readministration of helper-dependent adenoviral vectors to mouse airway mediated via transient immunosuppression.
Cao H; Yang T; Li XF; Wu J; Duan C; Coates AL; Hu J
Gene Ther; 2011 Feb; 18(2):173-81. PubMed ID: 20882053
[TBL] [Abstract][Full Text] [Related]
13. Generation of recombinant adenovirus vector with infectious adenoviral genome released from cosmid-based vector by simple procedure allowing complex manipulation.
Kojima H; Ohishi N; Yagi K
Biochem Biophys Res Commun; 1998 May; 246(3):868-72. PubMed ID: 9618304
[TBL] [Abstract][Full Text] [Related]
14. Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma.
Wolkersdörfer GW; Morris JC; Ehninger G; Ramsey WJ
J Gene Med; 2004 Jun; 6(6):652-62. PubMed ID: 15170736
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
16. Reexpression following readministration of an adenoviral vector in adult mice after initial in utero adenoviral administration.
Lipshutz GS; Flebbe-Rehwaldt L; Gaensler KM
Mol Ther; 2000 Oct; 2(4):374-80. PubMed ID: 11020353
[TBL] [Abstract][Full Text] [Related]
17. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
18. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII.
Andrews JL; Kadan MJ; Gorziglia MI; Kaleko M; Connelly S
Mol Ther; 2001 Mar; 3(3):329-36. PubMed ID: 11273775
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of costimulation allows for repeated systemic administration of adenoviral vector in rhesus monkeys.
Haegel-Kronenberger H; Haanstra K; Ziller-Remy C; Ortiz Buijsse AP; Vermeiren J; Stoeckel F; Van Gool SW; Ceuppens JL; Mehtali M; De Boer M; Jonker M; Boon L
Gene Ther; 2004 Feb; 11(3):241-52. PubMed ID: 14737083
[TBL] [Abstract][Full Text] [Related]
20. Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway.
Scaria A; St George JA; Gregory RJ; Noelle RJ; Wadsworth SC; Smith AE; Kaplan JM
Gene Ther; 1997 Jun; 4(6):611-7. PubMed ID: 9231078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
